Concurrent RB1 loss and &lt;i&gt;BRCA&lt;/i&gt;-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma. Here, RB1 is linked to serous adenocarcinoma.